Lyell Immunopharma, Inc.
LYEL
$22.31
$1.507.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -325.66M | -331.40M | -334.52M | -342.99M | -203.99M |
| Total Depreciation and Amortization | 14.17M | 16.28M | 18.05M | 19.63M | 19.66M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 157.01M | 152.99M | 150.80M | 164.09M | 29.97M |
| Change in Net Operating Assets | -10.53M | -9.36M | -9.44M | -3.12M | -1.43M |
| Cash from Operations | -165.02M | -171.48M | -175.12M | -162.39M | -155.79M |
| Capital Expenditure | -520.00K | -517.00K | -680.00K | -464.00K | -445.00K |
| Sale of Property, Plant, and Equipment | 263.00K | -- | -- | -- | -- |
| Cash Acquisitions | -31.35M | -31.35M | -31.35M | -31.35M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 170.57M | 169.40M | 201.92M | 154.23M | -31.33M |
| Cash from Investing | 138.97M | 137.54M | 169.90M | 122.42M | -31.77M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 50.62M | 621.00K | 1.30M | 1.40M | 1.85M |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -76.00K | -199.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 1.00K | -- | -- |
| Cash from Financing | 50.62M | 621.00K | 1.30M | 1.33M | 1.65M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.57M | -33.32M | -3.92M | -38.64M | -185.91M |